UNSPSC 51161533: Isbufylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C11H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9C8Z5F38D0, chemically known as 3,7-dihydro-1,3-dimethyl-7-(2-methylpropyl)-1h-purine-2,6-dione but generally known as isbufylline, which bears US NIH Compound Identifier 65681. European Medicines Agency schedules Isbufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08308MIG.

UNSPSC 51161533 Isbufylline is a Commodity code covering the procurement of specific pharmaceutical active ingredients and related products for state and local healthcare and human services agencies. State and local governments buy under this code primarily through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions; the mechanism consolidates procurement volume to negotiate competitive pricing and standardized supply chain relationships with pharmaceutical manufacturers and authorized wholesalers. The work involves manufacturers supplying products with specific National Drug Codes (NDCs), detailed product specifications (SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations), compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and the ability to distribute through authorized wholesaler networks with chargeback systems in place. Vendors must meet substantial insurance requirements (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000) and agree to performance penalties for violations such as late reporting, missed onboarding timelines, or improper class-of-trade denials. The issuing bodies in this space are multistate cooperative purchasing alliances and state procurement offices administering them on behalf of participating state and local government facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (solicitation number S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across Minnesota, Oregon, and other participating jurisdictions. Proposals were due March 26, 2026, with evaluation weighted heavily toward price competitiveness (75 percent), fixed pricing for the contract term (10 percent), compliance with administrative requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors will be provided to three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contracts effective July 1, 2026, for an initial two-year term with optional extensions at MMCAP's discretion through June 30, 2028.